May 26 (UPI) -- U.S. biotechnology company Novavax says it has entered clinical trials for a potential coronavirus vaccine, with first results expected within weeks.
The "NVX‑CoV2373" vaccine candidate has begun a combined Phase I/II preliminary immunogenicity and safety trial, Novavax announced Monday.
Results from the trial are expected in July, Novavax President and CEO Stanley Erck said.
"Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the fundamental need for a vaccine in the fight against the global COVID‑19 pandemic," he said in a statement. "We look forward to sharing the clinical results in July and, if promising, quickly initiating the Phase 2 portion of the trial."
Novavax said NVX‑CoV2373 demonstrated "high immunogenicity and high levels of neutralizing antibodies" during pre-clinical tests and showed "strong evidence" it will be effective in fighting COVID‑19 in humans.
Novavax's vaccine candidate joins a list of several others that are in clinical trials.
U.S. biotech firm Moderna announced last week positive stage-one results for its candidate and AstraZeneca said British researchers at the University of Oxford have begun enrolling subjects in its advanced-stage trial for its candidate.